Filing Flows › Comparisons › VERA vs NKTR
Vera Therapeutics vs Nektar Therapeutics: VERA and NKTR compared
Vera Therapeutics is the larger company: $10.3M of revenue in its latest quarter (Q3 2026) against $10.1M for Nektar Therapeutics (Q2 2026). Nektar Therapeutics is more profitable, with an operating margin of -417.9% against -931.2%.
Where the money goes: VERA and NKTR
Vera Therapeutics (VERA) · Q3 2026
Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%, net loss $93.7M, operating cash flow −$99.2M. The chart follows the revenue to costs, profit and cash.
Nektar Therapeutics (NKTR) · Q2 2026
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
| Vera Therapeutics (VERA) | Nektar Therapeutics (NKTR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $10.3M | $10.1M |
| Revenue growth, Y/Y | — | -9% |
| Operating margin | -931.2% | -417.9% |
| Net earnings | −$93.7M | −$40.6M |
| Net margin | -911.9% | -401.0% |
| Operating cash flow | −$99.2M | −$75.8M |
Questions
Which is bigger, Vera Therapeutics or Nektar Therapeutics?
Vera Therapeutics is the larger company: $10.3M of revenue in its latest quarter (Q3 2026) against $10.1M for Nektar Therapeutics (Q2 2026).
Is Vera Therapeutics or Nektar Therapeutics growing faster?
Nektar Therapeutics is more profitable, with an operating margin of -417.9% against -931.2%.
More: Vera Therapeutics earnings · how Vera Therapeutics makes money · Nektar Therapeutics earnings · how Nektar Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.